{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T15:04:16Z","timestamp":1789398256839,"version":"build-2803163510"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s10067-023-06632-6","type":"journal-article","created":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T19:02:35Z","timestamp":1684177355000},"page":"2237-2241","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Refractory alopecia in lupus treated with tofacitinib \u2014 a case-based review"],"prefix":"10.1007","volume":"42","author":[{"given":"Rajdeep","family":"Sarkar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakashini","family":"MV","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naga","family":"Hinduja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitanjali","family":"Sethy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hemanta","family":"Kar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4631-311X","authenticated-orcid":false,"given":"Sakir","family":"Ahmed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"6632_CR1","first-page":"1185","volume":"18","author":"AJ Wysenbeek","year":"1991","unstructured":"Wysenbeek AJ, Leibovici L, Amit M, Weinberger A (1991) Alopecia in systemic lupus erythematosus. Relation to disease manifestations. J Rheumatol 18:1185\u20131186","journal-title":"J Rheumatol"},{"key":"6632_CR2","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1346-8138.2007.00309.x","volume":"34","author":"SJ Yun","year":"2007","unstructured":"Yun SJ, Lee J-W, Yoon H-J et al (2007) Cross-sectional study of hair loss patterns in 122 Korean systemic lupus erythematosus patients: a frequent finding of non-scarring patch alopecia. J Dermatol 34:451\u2013455. https:\/\/doi.org\/10.1111\/j.1346-8138.2007.00309.x","journal-title":"J Dermatol"},{"key":"6632_CR3","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1007\/s11136-005-2638-9","volume":"15","author":"LB Ferraz","year":"2006","unstructured":"Ferraz LB, Almeida FA, Vasconcellos MR et al (2006) The impact of lupus erythematosus cutaneous on the quality of life: the Brazilian-Portuguese version of DLQI. Qual Life Res Int J Qual Life Asp Treat Care Rehabil 15:565\u2013570. https:\/\/doi.org\/10.1007\/s11136-005-2638-9","journal-title":"Qual Life Res Int J Qual Life Asp Treat Care Rehabil"},{"key":"6632_CR4","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.ijwd.2017.11.007","volume":"4","author":"DS Davis","year":"2018","unstructured":"Davis DS, Callender VD (2018) Review of quality of life studies in women with alopecia. Int J Womens Dermatol 4:18\u201322. https:\/\/doi.org\/10.1016\/j.ijwd.2017.11.007","journal-title":"Int J Womens Dermatol"},{"key":"6632_CR5","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/S0140-6736(18)31363-1","volume":"392","author":"DJ Wallace","year":"2018","unstructured":"Wallace DJ, Furie RA, Tanaka Y et al (2018) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Lond Engl 392:222\u2013231. https:\/\/doi.org\/10.1016\/S0140-6736(18)31363-1","journal-title":"Lancet Lond Engl"},{"key":"6632_CR6","doi-asserted-by":"publisher","first-page":"11788","DOI":"10.3390\/ijms231911788","volume":"23","author":"P Richter","year":"2022","unstructured":"Richter P, Cardoneanu A, Burlui AM et al (2022) Why do we need JAK inhibitors in systemic lupus erythematosus? Int J Mol Sci 23:11788. https:\/\/doi.org\/10.3390\/ijms231911788","journal-title":"Int J Mol Sci"},{"key":"6632_CR7","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.3390\/ijms23052505","volume":"23","author":"TM Sim","year":"2022","unstructured":"Sim TM, Ong SJ, Mak A, Tay SH (2022) Type I interferons in systemic lupus erythematosus: a journey from bench to bedside. Int J Mol Sci 23:2505. https:\/\/doi.org\/10.3390\/ijms23052505","journal-title":"Int J Mol Sci"},{"key":"6632_CR8","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1111\/j.1468-3083.2011.04388.x","volume":"27","author":"Y Gong","year":"2013","unstructured":"Gong Y, Ye Y, Zhao Y et al (2013) Severe diffuse non-scarring hair loss in systemic lupus erythematosus - clinical and histopathological analysis of four cases. J Eur Acad Dermatol Venereol JEADV 27:651\u2013654. https:\/\/doi.org\/10.1111\/j.1468-3083.2011.04388.x","journal-title":"J Eur Acad Dermatol Venereol JEADV"},{"key":"6632_CR9","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/S0140-6736(22)02546-6","volume":"401","author":"M Petri","year":"2023","unstructured":"Petri M, Bruce IN, D\u00f6rner T et al (2023) Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II). Lancet Lond Engl 401:1011\u20131019. https:\/\/doi.org\/10.1016\/S0140-6736(22)02546-6","journal-title":"Lancet Lond Engl"},{"key":"6632_CR10","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/1744666X.2022.2040988","volume":"18","author":"S Nakayamada","year":"2022","unstructured":"Nakayamada S, Tanaka Y (2022) Pathological relevance and treatment perspective of JAK targeting in systemic lupus erythematosus. Expert Rev Clin Immunol 18:245\u2013252. https:\/\/doi.org\/10.1080\/1744666X.2022.2040988","journal-title":"Expert Rev Clin Immunol"},{"key":"6632_CR11","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.jaad.2016.09.007","volume":"76","author":"LY Liu","year":"2017","unstructured":"Liu LY, Craiglow BG, Dai F, King BA (2017) Tofacitinib for the treatment of severe alopecia areata and variants: a study of 90 patients. J Am Acad Dermatol 76:22\u201328. https:\/\/doi.org\/10.1016\/j.jaad.2016.09.007","journal-title":"J Am Acad Dermatol"},{"key":"6632_CR12","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1159\/000494613","volume":"235","author":"N Almutairi","year":"2019","unstructured":"Almutairi N, Nour TM, Hussain NH (2019) Janus kinase inhibitors for the treatment of severe alopecia areata: an open-label comparative study. Dermatol Basel Switz 235:130\u2013136. https:\/\/doi.org\/10.1159\/000494613","journal-title":"Dermatol Basel Switz"},{"key":"6632_CR13","doi-asserted-by":"publisher","first-page":"e89776","DOI":"10.1172\/jci.insight.89776","volume":"1","author":"M Kennedy Crispin","year":"2016","unstructured":"Kennedy Crispin M, Ko JM, Craiglow BG et al (2016) Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata. JCI Insight 1:e89776. https:\/\/doi.org\/10.1172\/jci.insight.89776","journal-title":"JCI Insight"},{"key":"6632_CR14","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1056\/NEJMoa2110343","volume":"386","author":"B King","year":"2022","unstructured":"King B, Ohyama M, Kwon O et al (2022) Two phase 3 trials of baricitinib for alopecia areata. N Engl J Med 386:1687\u20131699. https:\/\/doi.org\/10.1056\/NEJMoa2110343","journal-title":"N Engl J Med"},{"key":"6632_CR15","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1007\/s00296-011-1999-3","volume":"31","author":"AY Gasparyan","year":"2011","unstructured":"Gasparyan AY, Ayvazyan L, Blackmore H, Kitas GD (2011) Writing a narrative biomedical review: considerations for authors, peer reviewers, and editors. Rheumatol Int 31:1409\u20131417. https:\/\/doi.org\/10.1007\/s00296-011-1999-3","journal-title":"Rheumatol Int"},{"key":"6632_CR16","doi-asserted-by":"publisher","first-page":"3391","DOI":"10.1038\/s41467-021-23361-z","volume":"12","author":"SA Hasni","year":"2021","unstructured":"Hasni SA, Gupta S, Davis M et al (2021) Phase 1 double-blind randomized safety trial of the Janus kinase inhibitor tofacitinib in systemic lupus erythematosus. Nat Commun 12:3391. https:\/\/doi.org\/10.1038\/s41467-021-23361-z","journal-title":"Nat Commun"},{"key":"6632_CR17","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jdcr.2021.09.030","volume":"20","author":"E Bonnardeaux","year":"2021","unstructured":"Bonnardeaux E, Dutz JP (2021) Oral tofacitinib citrate for recalcitrant cutaneous lupus. JAAD Case Rep 20:61\u201364. https:\/\/doi.org\/10.1016\/j.jdcr.2021.09.030","journal-title":"JAAD Case Rep"},{"key":"6632_CR18","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1093\/rheumatology\/keac309","volume":"61","author":"J Yang","year":"2022","unstructured":"Yang J, Li J, Shi L (2022) Successful remission with tofacitinib in a patient with refractory bullous systemic lupus erythematosus. Rheumatology 61:e341\u2013e343. https:\/\/doi.org\/10.1093\/rheumatology\/keac309","journal-title":"Rheumatology"},{"key":"6632_CR19","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1007\/s10067-017-3574-0","volume":"36","author":"JA Jaller","year":"2017","unstructured":"Jaller JA, Jaller JJ, Jaller AM et al (2017) Recovery of nail dystrophy potential new therapeutic indication of tofacitinib. Clin Rheumatol 36:971\u2013973. https:\/\/doi.org\/10.1007\/s10067-017-3574-0","journal-title":"Clin Rheumatol"},{"key":"6632_CR20","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1177\/0961203313508833","volume":"22","author":"Y Ye","year":"2013","unstructured":"Ye Y, Zhao Y, Gong Y et al (2013) Non-scarring patchy alopecia in patients with systemic lupus erythematosus differs from that of alopecia areata. Lupus 22:1439\u20131445. https:\/\/doi.org\/10.1177\/0961203313508833","journal-title":"Lupus"},{"key":"6632_CR21","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1136\/annrheumdis-2019-216571","volume":"79","author":"K Maeshima","year":"2020","unstructured":"Maeshima K, Shibata H (2020) Efficacy of JAK 1\/2 inhibition in the treatment of diffuse non-scarring alopecia due to systemic lupus erythematosus. Ann Rheum Dis 79:674\u2013675. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216571","journal-title":"Ann Rheum Dis"},{"key":"6632_CR22","doi-asserted-by":"publisher","first-page":"654376","DOI":"10.3389\/fimmu.2021.654376","volume":"12","author":"Y-L Chen","year":"2021","unstructured":"Chen Y-L, Liu L-X, Huang Q et al (2021) Case report: reversal of long-standing refractory diffuse non-scarring alopecia due to systemic lupus erythematosus following treatment with tofacitinib. Front Immunol 12:654376. https:\/\/doi.org\/10.3389\/fimmu.2021.654376","journal-title":"Front Immunol"},{"key":"6632_CR23","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s00296-021-04956-7","volume":"41","author":"RV Karalilova","year":"2021","unstructured":"Karalilova RV, Batalov ZA, Sapundzhieva TL et al (2021) Tofacitinib in the treatment of skin and musculoskeletal involvement in patients with systemic sclerosis, evaluated by ultrasound. Rheumatol Int 41:1743\u20131753. https:\/\/doi.org\/10.1007\/s00296-021-04956-7","journal-title":"Rheumatol Int"},{"key":"6632_CR24","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1136\/annrheumdis-2019-215455","volume":"78","author":"H You","year":"2019","unstructured":"You H, Zhang G, Wang Q et al (2019) Successful treatment of arthritis and rash with tofacitinib in systemic lupus erythematosus: the experience from a single centre. Ann Rheum Dis 78:1441\u20131443. https:\/\/doi.org\/10.1136\/annrheumdis-2019-215455","journal-title":"Ann Rheum Dis"},{"key":"6632_CR25","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1007\/s00296-022-05270-6","volume":"43","author":"CG Gialouri","year":"2023","unstructured":"Gialouri CG, Moustafa S, Thomas K et al (2023) Herpes zoster in patients with inflammatory arthritides or ulcerative colitis treated with tofacitinib, baricitinib or upadacitinib: a systematic review of clinical trials and real-world studies. Rheumatol Int 43:421\u2013435. https:\/\/doi.org\/10.1007\/s00296-022-05270-6","journal-title":"Rheumatol Int"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06632-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06632-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T07:11:21Z","timestamp":1689232281000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06632-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":25,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["6632"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06632-6","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]},"assertion":[{"value":"19 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed consent was obtained from the patient for publication.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}